摘要 |
<p>The invention relates to the field of minimal residual disease (MRD) diagnostics, which is progressively more applied for the evaluation of treatment effectiveness in patients with a hematological malignancy, such as B-cell precursor acute lymphoblastic leukemia (BCP-ALL), B-cell chronic lymphocytic leukemia (B-CLL), and multiple myeloma (MM). Provided are unique reagent compositions with carefully selected and thoroughly tested combinations of antibodies, for≧8-color flow cytometric stainings as well as for 10-color and 12-color flow cytometric stainings, which can reach sensitivities of at least 10−4, even down to 10−5. Also provided are diagnostic kits and methods for detecting MRD.</p> |
申请人 |
ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM |
发明人 |
VAN DONGEN, JACOBUS JOHANNES MARIA;ORFAO DE MATOS CORREIA E VALE, JOSÉ ALBERTO;FLORES MONTERO, JUAN ALEJANDRO;ALMEIDA PARRA, JULIA MARIA;VAN DER VELDEN, VINCENT HENRICUS JOHANNES;BÖTTCHER, SEBASTIAN;LANGERAK, ANTHONIE WILLEM;MEJSTRÍKOVÁ, ESTER;SZCZEPANSKI, TOMASZ;RITGEN, MATTHIAS;MONTEIRO DA SILVA LUCIO, PAULO JORGE |